MacroGenics reports Q2 EPS (57c), consensus (38c)

Reports Q2 revenue $22.24M, consensus $28.06M. “Over the past several years, MacroGenics (MGNX) has established itself as a pioneer in the field of antibody-based therapeutics for patients battling cancer. Today, we have a promising portfolio spanning antibody drug conjugates and multi-specifics that we believe has the potential to generate significant value for both patients and shareholders alike,” said Eric Risser, president and CEO of MacroGenics. “As we look ahead to the remainder of 2025 and beyond, we intend to drive MacroGenics to become an even more focused and capital-efficient biotechnology company as we advance our pipeline. In the coming quarters, we look forward to providing updates on our key strategic priorities related to pipeline and Company progress.”